The effect of human cord blood therapy on the intestinal tract of lethally irradiated mice: possible use for mass casualties.
OBJECTIVE
To evaluate the recovery of the gastrointestinal tract in lethally irradiated mice treated with human cord blood and antibiotics.


METHODS
A/J mice were randomly assigned to seven study groups, including groups exposed to acute 9 Gy from (137)Cs gamma-rays to the whole body. Four hours after irradiation, exposed mice were treated with either cord blood nucleated cells, Levaquin, or a combination of both. Weight gain/loss and survival were monitored for 2 months. Upon death or euthanasia, the organs were prepared for molecular and histological analyses.


RESULTS
Whereas irradiated mice (n = 9) lived 6-15 days, approximately 60% of irradiated mice that received the combined treatment (n = 7) survived more than 50 days. None of the treated animals developed Graft versus Host disease. All animals lost weight after irradiation; however, the 50(+) days-survivors (n = 4) gained on average approximately 1.8 g over their initial weight. Whereas hemorrhagic bone marrow and large areas of transmural necrosis were observed in the bowel of the irradiated mice, the 50(+) days-survivors showed recovery of the bone marrow. They behaved normally and had significant but incomplete recovery of the intestinal and colonic mucosa. Human DNA was detected in their organs, particularly in the large intestine.


CONCLUSIONS
Red cell-depleted cord blood transfusions combined with antibiotic treatment contribute to bone marrow and gastrointestinal recovery in high dose-irradiated mice, and may be an available therapy for mass casualties during radiological emergencies.
Azzam
Edouard I
EI
Department of Radiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103, USA. azzamei@umdnj.edu
Yang
Zhi
Z
Li
Min
M
Kim
Soyeon
S
Kovalenko
Olga A
OA
Khorshidi
Manoochehr
M
Ende
Norman
N
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D036101:Cord Blood Stem Cell Transplantation; D004247:DNA / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000637:transplantation*; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects* / Q000601:surgery*; D006801:Humans; D064704:Levofloxacin; D054527:Mass Casualty Incidents; D051379:Mice; D015242:Ofloxacin / Q000494:pharmacology; D015996:Survival Rate; D013997:Time Factors
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D004247:DNA; D015242:Ofloxacin